UPCOMING SESSIONS in ET
Thu, Jun 25, 2026
5:00 – 6:00 AM Bangkok
Neurological Manifestations of Amyloidosis — Managing Amyloidosis PN Richard Wlodarski Click To Register
UPCOMING SESSIONS in ET
Thu, Jun 25, 2026 · 5:00 – 6:00 AM Bangkok
Neurological Manifestations of Amyloidosis — Managing Amyloidosis PN
Richard Wlodarski
Click To Register
View all sessions

Single-arm, Multi-center Study Evaluating the Acceptance and Feasibility of a Digital Remote Monitoring Tool Configured for Patients With ATTR-CM: ACO-Monitor (ACO-MONITOR)

Source
ClinicalTrials.gov

Study Overview

Brief Summary

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a heart condition caused by a protein called transthyretin (TTR) building up as amyloid in the heart muscle. This build-up makes the heart stiff and can lead to symptoms of heart failure, such as difficulty breathing, tiredness, swelling in the legs, and reduced ability to be physically active. ATTR-CM occurs in two forms: a hereditary (variant) type caused by changes in genes, and a wild-type form that usually develops with aging.

People living with ATTR-CM are usually cared for at specialist centers, which may require them to travel long distances for appointments. Because of this, visits may be infrequent, and sometimes people only see their doctor once a year. This can make it harder to notice if the disease is getting worse or if there are problems with following their treatment plan. As a result, important changes in health may go unnoticed for several months, which can be risky.